Alpinia pricei (Zingiberaceae) is a spicy herb indigenous to Taiwan. A potent anti-inflammatory compound, flavokawain B (FKB), was obtained from A. pricei. FKB significantly inhibited production of NO and PGE(2) in LPS-induced RAW 264.7 cells. Moreover, it also notably decreased the secretion of TNF-alpha. Expression of iNOS and COX-2 proteins was also inhibited by FKB in a dose-dependent manner. FKB blocked the nuclear translocation of NF-kappaB induced by LPS, which was associated with prevention IkappaB degradation, and subsequently decreased NF-kappaB protein levels in the nucleus. Similar anti-inflammatory activities of FKB were observed in an animal assay. NO concentrations in mouse serum rose dramatically from 3.2 to 28.8 microM after mice were challenged with LPS; however, preadministration of 200 mg/kg FKB reduced the NO concentration to 3.8 microM after challenge with LPS. Moreover, FKB strongly suppressed LPS-induced iNOS, COX-2, and NF-kappaB proteins expression in mouse liver.
Objective. To investigate the association between early perihematomal edema (PHE) expansion and functional outcome in patients with intracerebral hemorrhage (ICH). Methods. Patients with ICH who underwent initial computed tomography (CT) scans within 6 hours after the onset of symptoms and follow-up CT scans within
24
±
12
hours were included. Absolute PHE increase was defined as the absolute increase in PHE volume from baseline to 24 hours. A receiver-operating characteristic (ROC) curve was generated to determine the cutoff value for early PHE expansion, which was operationally defined as an absolute increase in PHE volume of >6 mL. The outcome of interest was 3-month poor outcome defined as modified Rankin scale score of ≥4. A multivariable logistic regression procedure was used to assess the association between early PHE expansion and outcome after ICH. Results. In 233 patients with ICH, 89 (38.2%) patients had poor outcome at 3-month follow-up. Early PHE expansion was observed in 56 of 233 (24.0%) patients. Patients with early PHE expansion were more likely to have poor functional outcome than those without (43.8% vs. 11.8%,
p
<
0.001
). After adjusting for age, admission systolic blood pressure, admission Glasgow Coma Scale score, baseline ICH volume and the presence of intraventricular hemorrhage, and time from onset to CT, early PHE expansion was associated with poor outcome (adjusted odds ratio, 4.25; 95% confidence interval, 1.70–10.60;
p
=
0.002
). Conclusions. The early PHE expansion was not uncommon in patients with ICH and was correlated with poor outcome following ICH.
The inherent porous structures and aligned functional units inside the skeleton of covalent organic frameworks (COFs) provide an extraordinary promise for post-modification and deservedly expand their application in the field of proton conduction. Herein, we tactfully introduced copper ions into a two-dimensional COF (TpTta) furnished with ample N,Ochelating sites by a post-modification strategy to achieve two copper(II)-modified products, namely, CuCl
IntroductionThe overall effect of pamidronate on bone mass density (BMD) in the early renal transplant period varies considerably among studies. The effects of pamidronate on graft function have not been determined.Materials and MethodsA comprehensive search was conducted in PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL) and Embase independently by two authors. Randomized controlled trials of pamidronate evaluating bone loss in the first year of renal transplantation were included. Methods reported in the “Cochrane Handbook for Systematic Reviews of Interventions 5.0.2” were used to evaluate changes of lumbar spine and femoral neck BMD, and serum creatinine, calcium and intact parathyroid hormone (iPTH) levels. Fixed or random effect models were used as appropriate.ResultsSix randomized trials evaluating 281 patients were identified. One hundred forty-four were treated with pamidronate and 137 were control patients. Administration of pamidronate was associated with significant reduction of bone loss in the lumbar spine, compared to the control group (standardized mean difference (SMD) = 24.62 [16.25, 32.99]). There was no difference between the pamidronate treated and control femoral neck BMD (SMD = 3.53 [−1.84, 8.90]). A significant increase in the serum creatinine level of the intervention group was seen, compared to the control group. The serum calcium and iPTH of the pamidronate and control groups were not different after 1 year (serum creatinine: SMD = −3.101 [−5.33, −0.89]; serum calcium: SMD = 2.18 [−0.8, 5.16]; serum iPTH: SMD = 0.06 [−0.19, 0.31]). Heterogeneity was low for serum calcium and iPTH and high for serum creatinine.ConclusionsThis meta-analysis demonstrated the beneficial clinical efficacy of pamidronate on BMD with no association with any alteration in graft function during the first year of renal transplantation. Significant heterogeneity precludes the conclusion of the relationship between serum creatinine and pamidronate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.